VBI Vaccines (VBIV) PT Lowered to $5 at Canaccord Genuity
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 11/4/2026
- Wall Street rallies after Democrats win Congress; data center stocks slide
- What the Democratic sweep in the midterms means for markets
- SpaceX, Tesla slide as election risks mount, Morgan Stanley turns bullish
- CVS Health plans to split into two public companies by 2028
- AI sector outlook darkens as Democrat wins threaten $900B capex cycle
Tweet
Share
E-mailGet Alerts VBIV Hot Sheet
Price: $0.07 --0%
Rating Summary:
7 Buy, 0 Hold, 0 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 16 | Down: 25 | New: 12
Rating Summary:
7 Buy, 0 Hold, 0 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 16 | Down: 25 | New: 12
Join SI Premium – FREE
Canaccord Genuity analyst John Newman lowered the price target on VBI Vaccines (NASDAQ: VBIV) to $5.00 (from $10.00) while maintaining a Buy rating.
Analyst comments: "We maintain our BUY rating and are reducing our price target to $5 from $10 after moderating our launch estimate in the US due to less-clear competitive positioning vs Heplisav-B. We continue to believe Sci-B-Vac will be viewed positively by regulators and achieve approval in the US and EU after positive readout in CONSTANT later this year."
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Dynatrace Inc. (DT) PT Lowered to $60 at DA Davidson
- TETRA Technologies Inc. (TTI) PT Lowered to $11 at Stifel
- Leidos Holdings (LDOS) PT Lowered to $138 at Stifel
Create E-mail Alert Related Categories
Analyst Comments, Analyst PT ChangeRelated Entities
Canaccord GenuitySign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
